Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enveric Biosciences filings document a biotechnology issuer focused on neuroplastogenic small-molecule drug candidates for psychiatric and neurological disorders. Its periodic and current reports address operating results, pipeline updates for EB-003 and related molecule series, intellectual-property matters, risk factors and the use of investor presentation materials in Regulation FD disclosures.
The company’s SEC record also covers capital-structure and governance matters, including registered direct and private placement financings, at-the-market offering registration, common stock, pre-funded warrants, Series G, H, I and J warrants, resale registration obligations, and Nasdaq-listed common stock. Proxy materials describe director elections, executive-compensation votes, auditor ratification, reverse stock split proposals and authorized-share proposals.
Enveric Biosciences, Inc. furnished a Q2 2026 investor presentation under Regulation FD. The company plans to post this Investor Presentation on its website and use it in discussions with current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, and employees.
The Investor Presentation is attached as Exhibit 99.1 and is also accessible via the company’s investor events webpage. The information in this report, including Exhibit 99.1, is furnished rather than filed under the Exchange Act, limiting its treatment under Section 18 and other incorporation-by-reference provisions.
Coveney Kevin Michael reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences, Inc. reported that Chief Financial Officer Kevin Michael Coveney received a grant of 133,333 restricted stock units under the company’s 2020 Long-Term Incentive Plan. These RSUs are a form of equity compensation and were granted at no cash cost per unit.
For each vested RSU, Coveney will receive one share of common stock, bringing his total reported direct holdings to 180,746 shares after the grant. One-fourth of the RSUs will vest on the one-year anniversary of the grant date, then one‑thirty‑sixth will vest each month, with any remaining RSUs vesting on the fourth anniversary, all conditioned on continued employment.
Enveric Biosciences, Inc. CEO Joseph Edward Tucker received a grant of 201,124 restricted stock units of common stock under the company’s 2020 Long-Term Incentive Plan. These RSUs have no cash exercise price; one share of common stock will be issued for each vested unit. One-fourth of the RSUs will vest on the one-year anniversary of the grant date, with an additional one‑thirty‑sixth vesting each month thereafter, and any remaining RSUs vesting on the fourth anniversary, subject to continued employment. Following this award, Tucker directly holds 271,479 shares of common stock.
PASQUALONE FRANK reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Frank Pasqualone received a grant of restricted stock. He was awarded 18,518 shares of common stock at no cash cost under the company’s 2020 Long-Term Incentive Plan. These shares will vest over time according to the plan and his award agreement.
After this equity grant, Pasqualone directly holds 26,423 shares of Enveric Biosciences common stock. This filing reflects a compensation-related stock award rather than an open-market purchase or sale.
WEBB MICHAEL D reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Michael D. Webb received a grant of 18,518 shares of restricted common stock. The award was made under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan as amended, with vesting governed by the plan and his restricted stock agreement.
These shares were granted at no cash cost per share and are compensation rather than an open-market purchase. Following this grant, Webb directly holds a total of 26,416 shares of Enveric Biosciences common stock, subject to the vesting terms of the award.
Schabacker Marcus reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Marcus Schabacker received a grant of 18,518 shares of restricted common stock under the company’s 2020 Long-Term Incentive Plan. The grant was awarded at no cash cost to him and will vest according to the plan and his award agreement. After this grant, he directly holds 26,418 shares of Enveric common stock.
Kegler George A. reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director George A. Kegler received a grant of 18,518 shares of restricted common stock on June 1, 2026 under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended. The grant was awarded at $0.0000 per share as equity compensation.
After this award, Kegler directly holds 26,418 shares of Enveric Biosciences common stock. The restricted shares will vest over time in line with the terms of the 2020 Long-Term Incentive Plan and his restricted stock award agreement.
DeWitt Sheila reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Sheila DeWitt received a stock grant reported on Form 4. She was granted 18,518 shares of restricted common stock at no cash cost, issued under Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan. After this award, she holds 26,306 common shares directly.
Enveric Biosciences, Inc. granted Chief Innovation Officer Peter J. Facchini 25,000 restricted stock units of common stock under its 2020 Long-Term Incentive Plan. Each unit will convert into one share of common stock as it vests, subject to continued employment.
One-fourth of the RSUs vest after one year, with an additional one-thirty-sixth vesting monthly until any remaining units vest on the fourth anniversary of grant. Following this award, Facchini holds 27,755 shares of common stock, adjusted for a prior 12-for-1 reverse stock split effective October 28, 2025.
Enveric Biosciences, Inc. reported two main developments. First, the board approved new standard forms of restricted stock unit (RSU) and restricted stock (RSA) award agreements under its 2020 Long-Term Incentive Plan. The RSUs vest over four years, while RSAs vest on specified dates, and both include change in control, forfeiture, and other customary terms for executives and directors.
Second, at the May 28, 2026 annual meeting, 991,828 shares were represented, equal to 52.54% of shares entitled to vote, establishing a quorum. Stockholders elected six directors and approved the advisory say-on-pay proposal with 569,552 votes for and 26,884 against. They extended board authority to implement a reverse stock split within a 1-for-5 to 1-for-15 range (793,344 for, 190,175 against), but voted against increasing authorized common shares to 5,000,000,000 (427,158 for, 555,147 against). The appointment of CBIZ CPAs P.C. as auditor for 2026 was ratified with 960,728 votes for and 19,347 against.